SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.

Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...

Concussions and traumatic brain injuries have been considered a potential cause of ALS, also known as Lou Gehrig's disease. But a new study argues the association might be the other way around, with ...